$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Check Out What Whales Are Doing With MRNA
Gilead Sciences Analyst Ratings
Biomarin Pharmaceutical Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
Oppenheimer Outlined a Top Buy and Sell Idea for Each S&P Sector
Here Are Big Pharma's Leading Blockbuster Makers
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Check Out What Whales Are Doing With GILD
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Decoding Moderna's Options Activity: What's the Big Picture?
Vertex Pharmaceuticals Analyst Ratings
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch